Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Phase 1

Completed

Brief Summary: This is a Phase 1, fixed sequence, open-label study to evaluate the effect of multiple oral doses of rabeprazole on the pharmacokinetics of a single dose of vadadustat 300 mg in healthy male and female subjects.

Detailed Description: This is a Phase 1, fixed sequence, open-label study in healthy adult subjects to evaluate the effect of multiple doses of rabeprazole on the pharmacokinetics of a single dose of vadadustat in healthy male and female subjects. Approximately twenty (20) subjects, with at least 30% female subjects, will be enrolled to ensure 18 evaluable subjects. Subjects will be on study for up to 66 days, including a 28-day screening period, 9-day clinic period, and a 30-day follow- up period post last dose. Subjects who are confirmed eligible and receive at least one dose of study drug will be considered enrolled in the study. Blood samples for PK analysis will be collected at pre-defined time points throughout the study up to 48 hours post administration of vadadustat.

Recruitment & Eligibility

Inclusion Criteria

Healthy Male or female between 18 and 55 years of age, inclusive, at time of informed consent
Body mass index between 18.0 and 30.0 kg/m2, with a minimum body weight of 45 kg for females and 50 kg for males, inclusive.

Exclusion Criteria

Current or past clinically significant history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease. History of cancer (except treated non-melanoma skin cancer) or history of chemotherapy use within 5 years prior to Screening.
Positive test results for human immunodeficiency virus (HIV) antibody; Positive test results of hepatitis B surface antigen (HBsAg), or positive hepatitis C virus antibody (HCVab) within 3 months prior to screening , or positive test results for human immunodeficiency virus antibody (HIVab) at Screening
Taking any prescription medication or over the counter multi-vitamin supplement, or any non-prescription products (including herbal-containing preparations but excluding acetaminophen) within 14 days prior to Day -1.

Arm && Interventions

Group	Intervention	Description
Rabeprazole and Vadadustat	Vadadustat	Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
Rabeprazole and Vadadustat	Rabeprazole	Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6

Primary Outcome Measures

Name	Time	Method
Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) for vadadustat	Up to 10 weeks
Area under plasma concentration-time curve from 0 to infinity (AUCinf) for vadadustat	Up to 10 weeks
Maximum observed plasma concentration (Cmax) for vadadustat	Up to 10 weeks

Secondary Outcome Measures

Name	Time	Method
Time to maximum observed plasma concentration (Tmax) of vadadustat	Up to 10 weeks
Reporting of treatment emergent adverse event (TEAE) as reported by study subjects	Up to 10 weeks
Area under plasma concentration-time curve from 0 to infinity (AUCinf) of vadadustat-O-glucuronide	Up to 10 weeks
Maximum observed plasma concentration (Cmax) of vadadustat-O-glucuronide	Up to 10 weeks
Percent of extrapolated area under the curve from time t to infinity (%AUCextrap) of vadadustat	Baseline and end of study
Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast) of vadadustat-O-glucuronide	Up to 10 weeks
Elimination rate constant (Kel) of vadadustat	Up to 10 weeks
Terminal half-life (t½) of vadadustat	Up to 10 weeks
Apparent total body clearance (CL/F) of vadadustat	Up to 10 weeks

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial